Indication
In combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for the treatment of resectable non‑small cell lung carcinoma at high risk of recurrence in adults.
Medicine details
- Medicine name:
- pembrolizumab (Keytruda)
- SMC ID:
- SMC2688
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 11 November 2024
- SMC meeting date:
- 01 October 2024
- Patient group submission deadline:
- 06 August 2024